Retatrutide is a triple-agonist research peptide that simultaneously activates GIP, GLP-1, and glucagon receptors. It is currently under intensive preclinical and research investigation for its potent effects on energy homeostasis, glucose metabolism, lipid profiles, and significant body-weight reduction in obesity and metabolic disorder models.
• Purity: ≥99% (HPLC verified)
• Sequence: 39-amino-acid linear peptide with C20 fatty diacid acyl chain
• CAS No.: 2381089-83-2
• Molecular Formula: C₂₂₃H₃₄₃F₃N₄₆O₇₀ (approximate, includes lipidation)
• Molecular Weight: ~4731.4 g/mol
• Form: Lyophilized powder
• Solubility: Reconstitute with bacteriostatic water or sterile saline (forms clear solution)
• Storage: Freeze-dried at -20°C; reconstituted at 2–8°C for up to 30 days
• Includes: Third-party Certificate of Analysis (COA) with every order
Disclaimer: This product is sold strictly for laboratory and in-vitro research purposes only. It is not intended for human or animal consumption, medical, diagnostic, therapeutic, or veterinary use. Not evaluated by Health Canada or the FDA. The purchaser is solely responsible for ensuring compliance with all applicable laws and regulations in Quebec, Canada.
